BIOLUTION GMBH

Their core work

Biolution GmbH is a Vienna-based biotechnology SME that contributes specialized scientific and analytical capabilities to European research consortia in the life sciences. Their H2020 involvement spans two distinct but related biomedical domains: epidemiological research on thyroid disease and iodine deficiency, and translational oncology targeting ALK kinase activation in cancer. As a small private company, they typically serve as a specialist contributor within larger multi-partner consortia rather than driving project coordination. Their value to research teams lies in niche technical expertise that complements the broader investigative efforts of academic and clinical partners.

What they specialise in

How they've shifted over time

Both of Biolution's H2020 projects launched in 2015, which makes meaningful temporal evolution analysis impossible — there is no early vs. late period to compare. The two projects run in parallel rather than sequentially, and no keyword metadata is available for either. What can be said is that even within a narrow two-project window, the organization spanned both endocrinology (EUthyroid) and oncology (ALKATRAS), suggesting a deliberately broad positioning across biomedical research service niches rather than deep specialization in a single disease area.

With both projects concluded by 2019 and no recorded H2020 activity since, it is unclear whether Biolution has continued in EU-funded research — any future collaboration would require direct verification of current capabilities and active status.

How they like to work

Biolution has never coordinated an H2020 project and joined both consortia in supporting roles — once as a formal participant, once as a third-party partner. This pattern is consistent with a small specialist company that adds targeted technical value without taking on administrative or scientific leadership responsibilities. Their exposure to 52 unique partners across 27 countries through just two projects reflects participation in large, geographically diverse consortia rather than a tightly repeated network of close collaborators.

Biolution has engaged with 52 unique consortium partners spanning 27 countries through only two projects, indicating participation in large pan-European research networks with broad geographic diversity. No recurring partner relationships can be identified from available data.

What sets them apart

Biolution occupies an unusual niche as an Austrian biotech SME operating simultaneously across endocrinology and oncology research, suggesting flexible analytical or platform capabilities applicable to multiple disease areas. Their third-party role in an MSCA training network alongside a direct RIA participation indicates they are recognized by academic consortia as a credible industrial contributor at different levels of project involvement. For consortium builders, they represent a compact, specialist industrial partner from an underrepresented Central European country with demonstrated commitment to clinically relevant biomedical research.

Highlights from their portfolio

• EUthyroid
  Biolution's only funded project, receiving the full EUR 376,276 allocation as a formal participant in a large pan-European RIA addressing a significant public health problem affecting millions across Europe.
• ALKATRAS
  Participation as a third-party industrial partner in an MSCA Innovative Training Network targeting cancer — a different funding instrument and disease area, demonstrating cross-programme versatility.